Hologic, Inc. (NASDAQ: HOLX) upgraded to Buy with price target $41 by Needham
Needham upgraded Hologic, Inc. (NASDAQ: HOLX) to Buy with price
target $41. Previously Needham upgraded to Hologic, Inc. (NASDAQ: HOLX) to Hold on 03/05/2015, when the stock price was $31.60.
Hologic Inc. is a leading supplier of high quality, innovative and clinically valuable diagnostic systems and tests. The company develops, manufactures and markets X-ray bone densitometers and ultrasound bone analyzers that address a growing market for osteoporosis prevention and treatment -- a key element of women's health care. The systems are used by more leading medical schools, universities and osteoporosis opinion leaders than any other bone densitometer.
& Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham
& Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.